Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Change in Receivables (2016 - 2026)

Champions Oncology has reported Change in Receivables over the past 14 years, most recently at $498000.0 for Q1 2026.

  • Quarterly results put Change in Receivables at $498000.0 for Q1 2026, down 90.55% from a year ago — trailing twelve months through Jan 2026 was -$3.7 million (down 147.65% YoY), and the annual figure for FY2025 was $1.4 million, down 27.88%.
  • Change in Receivables for Q1 2026 was $498000.0 at Champions Oncology, down from $2.1 million in the prior quarter.
  • Over the last five years, Change in Receivables for CSBR hit a ceiling of $5.3 million in Q1 2025 and a floor of -$4.5 million in Q2 2025.
  • Median Change in Receivables over the past 5 years was $250000.0 (2024), compared with a mean of $260764.7.
  • Biggest five-year swings in Change in Receivables: crashed 353.49% in 2023 and later soared 2500.0% in 2024.
  • Champions Oncology's Change in Receivables stood at -$276000.0 in 2022, then tumbled by 317.39% to -$1.2 million in 2023, then soared by 206.68% to $1.2 million in 2024, then soared by 69.08% to $2.1 million in 2025, then plummeted by 76.03% to $498000.0 in 2026.
  • The last three reported values for Change in Receivables were $498000.0 (Q1 2026), $2.1 million (Q4 2025), and -$1.8 million (Q3 2025) per Business Quant data.